Author(s):
Christophorus Aditya Pawitan, Yulia Fatima Bessing, Erikavitri Yulianti
Email(s):
dryulia@rsjrw.id
DOI:
10.52711/0974-360X.2025.00029 
Address:
Christophorus Aditya Pawitan1,2, Yulia Fatima Bessing3*, Erikavitri Yulianti4,2
1Psychiatry Resident, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
2Dr. Soetomo General Hospital, Surabaya, Indonesia.
3Psychogeriatric, Dr. Radjiman Wediodiningrat Mental Hospital, Lawang, Indonesia.
4Department of Psychiatry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 1,
Year - 2025
ABSTRACT:
Older persons are most commonly affected by Alzheimer's disease (AD). In this case study, there is a challenge in diagnosing mixed Alzheimer Disease (AD) and Dementia Lewy Bodies (DLB). A 89 years old patient from outpatient clinic had clinical feature of AD but also of DLB. In discussion, we analyzed the core feature of DLB in mixed case AD-DLB, because AD symptom said to be more dominant in mixed case, which may cause the low awareness of DLB. Its important that DLB diagnosed as soon as possible, especially due to the sensitivity toward antipsychotic. And lastly, there might be a need for further discussion of mixed type AD-DLB clinical feature for use in clinical setting
Cite this article:
Christophorus Aditya Pawitan, Yulia Fatima Bessing, Erikavitri Yulianti. Identifying Dementia Lewy Bodies in Alzheimer Dementia: Case Report. Research Journal of Pharmacy and Technology. 2025;18(1):191-5. doi: 10.52711/0974-360X.2025.00029
Cite(Electronic):
Christophorus Aditya Pawitan, Yulia Fatima Bessing, Erikavitri Yulianti. Identifying Dementia Lewy Bodies in Alzheimer Dementia: Case Report. Research Journal of Pharmacy and Technology. 2025;18(1):191-5. doi: 10.52711/0974-360X.2025.00029 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-1-29
REFERENCES:
1. Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. J Prev Alzheimer’s Dis. 2021; 1–16. doi:10.14283/jpad.2021.23.
2. Aanandhi MV, Kumar BYP, Chowdary PR, Praveen D. A review on the role of presenilin in alzheimer’s disease. Res J Pharm Technol. 2018; 11(5): 2149. doi:10.5958/0974-360X.2018.00397.9.
3. Velraj M, Lavaniya N. Alzheimer disease and a potential role of herbs-A review. Res J Pharm Technol. 2018; 11(6): 2695. doi:10.5958/0974-360X.2018.00498.5.
4. Choi EJ, Kim BJ, Kim HJ, Kwon M, Han NE, Lee SM, et al. False memory and Alzheimer’s disease pathology in patients with amnestic mild cognitive impairment: A study with amyloid PET. Dement Geriatr Cogn Dis Extra. 2021; 11(2): 172–80.
5. Sravani M, Lakshmi PS, Reddy KA, Deepthi NN, Kantheti USK. Insilico Analysis and Docking of Tacrine and Donepezil Derivatives Targeting Histamine-NMethyltransferase and Acetyl Cholinesterase Protein Respectively for Alzheimer’s Disease. Res J Pharm Technol. 2013; 6(1): 8.
6. Kumar SB. Role of Caffeine in Dementia, Alzheimer’s, Parkinsonism, Bipolar Mood Disorder. Res J Pharm Technol. 2015; 8(11): 1582. doi:10.5958/0974-360X.2015.00282.6.
7. Koeglsperger T, Rumpf SL, Schließer P, Struebing FL, Brendel M, Levin J, et al. Neuropathology of incidental Lewy body and prodromal Parkinson’s disease. Mol Neurodegener. 2023; 18(1): 32.
8. Yamada M, Komatsu J, Nakamura K, Sakai K, Samuraki-Yokohama M, Nakajima K, et al. Diagnostic criteria for dementia with Lewy bodies: updates and future directions. J Mov Disord. 2020; 13(1): 1.
9. Liyanagedera S, Bracewell RM, Larner AJ. Diagnosing dementia with Lewy bodies: new diagnostic criteria. J R Coll Physicians Edinb. 2018; 48(1): 44–5.
10. Pai V, Chandrashekar KS, Shreedhara CS, Pai A. In-Silico and In-Vitro correlation studies of natural β-secretase inhibitor: An approach towards Alzheimer’s Disease. Res J Pharm Technol. 2017; 10(10): 3506. doi:10.5958/0974-360X.2017.00628.X.
11. Thomas AJ, Mahin-Babaei F, Saidi M, Lett D, Taylor JP, Walker L, et al. Improving the identification of dementia with Lewy bodies in the context of an Alzheimer’s-type dementia. Alzheimers Res Ther. 2018; 10: 1–9.
12. Levenson JL. The American Psychiatric Association Publishing textbook of psychosomatic medicine and consultation-liaison psychiatry. American Psychiatric Pub; 2018.
13. Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease. Brain. 2021; 144(7): 2186–98.
14. Karati D, Kumar Shaw T. Pharmacological importance of Bacopa monnieri on Neurological disease (Alzheimer’s Disease) and Diabetic neuropathy - A Concise Review. Res J Pharm Technol. 2022; 3790–5. doi:10.52711/0974-360X.2022.00636.
15. Wee KW, Ilyas M, Nodrin S, Zubaidi A, Atif A. Unique Alzheimer’s Disease Challenges at less Urban Area: Case Reports in Malaysia. Res J Pharm Technol. 2018; 11(9): 4033. doi:10.5958/0974-360X.2018.00742.4.
16. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017; 89(1): 88–100. doi:10.1212/WNL.0000000000004058.
17. Leong MY, Mogana R, Selvaraja M, Chinnappan S, Por CS, Yap CS, et al. A Review on Herbal Skincare Creams. Curr Trends Biotechnol Pharm. 2021; 15(4): 455–70. doi:10.5530/ctbp.2021.4.48.
18. kanthamma SL, Kriszhnamurthi J, Hemalatha CN, Aanandhi MV. Insilico approach of interaction studies in Bacopa monnieri compounds targeting multi-proteins for Alzheimer’s Disease. Res J Pharm Technol. 2018; 11(4): 1522. doi:10.5958/0974-360X.2018.00283.4.
19. Sanmugam K. Depression is a Risk Factor for Alzheimer Disease-Review. Res J Pharm Technol. 2015; 8(8): 1056. doi:10.5958/0974-360X.2015.00181.X.
20. Ying TK, Shukkoor MSA, Khalivulla SI. In silico screening of selected flavanones for HMG CoA reductase inhibitory activity. Curr Trends Biotechnol Pharm. 2020; 14(5): 128–39. doi:10.5530/ctbp.2020.4s.14.
21. Iannaccone S, Houdayer E, Spina A, Nocera G, Alemanno F. Quantitative EEG for early differential diagnosis of dementia with Lewy bodies. Front Psychol. 2023; 14: 1150540.
22. Jellinger KA. Neuropathology of the Alzheimer’s continuum: an update. Free Neuropathol. 2020;1.
23. Naasan G, Shdo SM, Rodriguez EM, Spina S, Grinberg L, Lopez L, et al. Psychosis in neurodegenerative disease: differential patterns of hallucination and delusion symptoms. Brain. 2021; 144(3): 999–1012.
24. Hamilton CA, Matthews FE, Allan LM, Barker S, Ciafone J, Donaghy PC, et al. Utility of the pareidolia test in mild cognitive impairment with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry. 2021; 36(9): 1407–14.
25. Nelson RS, Abner EL, Jicha GA, Schmitt FA, Di J, Wilcock DM, et al. Neurodegenerative pathologies associated with behavioral and psychological symptoms of dementia in a community-based autopsy cohort. Acta Neuropathol Commun. 2023; 11(1): 89.
26. Tsunoda N, Hashimoto M, Ishikawa T, Fukuhara R, Yuki S, Tanaka H, et al. Clinical features of auditory hallucinations in patients with dementia with Lewy bodies: a soundtrack of visual hallucinations. J Clin Psychiatry. 2018; 79(3): 1673.
27. Tamilselvan M, Tamilanban T, Chitra V. Unfolding Remedial Targets for Alzheimer’s Disease. Res J Pharm Technol. 2020; 13(6): 3021. doi:10.5958/0974-360X.2020.00534.X.